AUSTIN, Texas and TOKYO, Nov. 14, 2025 /PRNewswire/ -- According to DataM Intelligence, the Cardiovascular Biologics Market Size was valued at approximately USD 2.20 billion in 2024 and is projected ...
Late-breaking results from clinical trials, debates about lifestyle choices and cardiovascular risk, and improving clinical care with generative AI are among the topics being presented by UC San ...
Catherine, born with Down syndrome and Tetralogy of Fallot (TOF), a rare congenital heart condition, has regained her quality of life after undergoing a novel Venus P™ valve implantation at the ...
November 13, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it ...
The first ever "humanized" model for aortic valve calcification paves the way for testing potential treatments.
(HealthDay News) — The prevalence of moderate or greater valvular heart disease (VHD) in the United States is 8.2 percent, according to a study presented at the 2025 Transcatheter Cardiovascular ...
Edwards Lifesciences (NYSE: EW) announced today that it provided the founding sponsorship for a new AHA Heart Valve ...
Biomedical engineers at Duke University have shown that a genetic mutation that causes congenital heart disease also ...
Valvular heart disease contributes to symptomatic heart failure, but its prevalence and prognostic significance in advanced heart failure is not well understood. There were 936 patients with advanced ...
Childhood cancer survivors who were exposed to heart radiation therapy or high cumulative anthracycline doses face increased risks for valvular heart disease. Greater exposure to platinum-based agents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback